Table 3

Univariate and logistic regression analysis of metabolic syndrome of 250 patients
Variable With MS N (%) or Mean ± SD Without MS N (%) or Mean ± SD Unadjusted OR (95% CI) Adjusted OR (95% CI)
Age (years) 45.1 ± 10.4 39.5 ± 12.2 1.04 (1.02 –1.07) 0.98 (0.93 – 1.03)
Gender
Female 38 (55.9%) 30 (44.1%) 2 (1.1 – 3.5) 1.91 (0.64 – 5.69)
Male 71 (39%) 111 (61%)
Duration
< 10 years 90 (42.3%) 123 (57.7%) 2.2 (1.3 – 3.8) 1.94 (0.62 – 6.01)
>10 years 19 (51.4) 18 (48.6%)
Smoking
Yes 55 (35.1%) 98 (64.9%) 2.2 (1.3 – 3.8) 2.16 (0.82 – 5.69)
No 54 (55.7%) 43 (44.3%)
Marital status
Married 53 (47.3%) 59 (52.7%) 0.76 (0.46 – 1.25)
Single 56 (40.6%) 82 (59.4%)
Education
< 12 years 90 (42.3%) 123 (57.7%) 1.4 (0.7 – 2.9)
>12 years 19 (51.4%) 18 (48.6%)
Occupation
Employed 12 (38.7%) 19 (61.3%) 0.8 (0.36 – 1.7)
Unemployed 97 (44.3%) 122 (55.7%)
Family history of DM
Yes 52 (46.4%) 60 (53.6%) 1.2(0.75 – 2.04)
No 57 (41.3%) 81 (57.7%)
CPZeq (mg) 432 ± 284.3 440.6 ± 269.7 1(0.9 – 1)
Therapeutic Regimen
Monotherapy 53 (42.7%) 71 (57.3%) 1.07(0.65 – 1.8)
Combination 56 (44.4%) 70 (55.6%)
Depot antipsychotic
Yes 68 (49.3) 70 (50.7%) 1.7 (1.01 – 2.8) 1.74 (0.73 – 4.14)
No 41 (36.6%) 71 (63.4%)
Olanzpine/Clozapine
Yes 10 (33.3%) 20 (66.7%) 0.61 (0.3 – 1.4)
No 99 (45%) 121 (55%)
WC (cm) 105.1 ± 13.2 92.3 ± 10.7 1.1 (1.07 – 1.1) 1.09 (1.05 – 1.13)
Systolic BP (mmHg) 131.1 ± 12.9 118.9 ± 13.2 1.07 (1.05 – 1.1) 1.11 (1.07 – 1.16)
Diastolic BP (mmHg) 78.4 ± 10.1 73.2 ± 10.9 1.05 (1.02 – 1.07) 0.96 (0.92 – 1.01)
TG (mg/dl) 256.4 ± 224.6 144.3 ± 115.4 1 (1 – 1) 1.01 (1.0 – 1.01)
HDL (mg/dl) 42.4 ± 11.8 46.2 ± 9.9 0.96 (0.94 – 0.99) 0.95 (0.91 – 1.00)
LDL (mg/dl) 121.7 ± 36.8 112.1 ± 39.1 1 (1 – 1.01)
FPG (mg/dl) 120.5 ± 64.5 83.3 ± 13.9 1.05 (1.03 – 1.07) 1.06 (1.03 - 1.09)

Abbreviations: SD, Standard deviation; OR, Odds ratio; CI, confidence interval; MS, Metabolic syndrome; DM, diabetes mellitus; WC, Waist Circumference; HDL, High-density lipoprotein; LDL, low-density lipoprotein; BP, Blood pressure; TG, triglyceride; FPG, Fasting plasma glucose; CPZeq, Chlorpromazine equivalents.

Sweileh et al.

Sweileh et al. BMC Psychiatry 2012 12:235   doi:10.1186/1471-244X-12-235

Open Data